CHAI Simple Tool Training Video
The CHAI Simple Tool is a morbidity-based forecasting tool that quantifies ARV needs over a three year period for an HIV/AIDS treatment...
top of page
A framework to support new product introduction in national health systems
Resource Library
Feb 27, 2023
Community Statements on DRV/r Use in 2L
In December 2022, 40+ community groups and an additional 45+ individuals released a community position statement calling on the global...
76
Feb 16, 2023
CHAI Simple Tool Adults & Pediatrics
Updated: Feb 15, 2023 The CHAI Simple Tool is a morbidity-based forecasting tool that quantifies ARV needs over a three year period for...
804
Apr 13, 2022
Adult DRV/r (400/50mg) FAQs for Communities and PLHIV
CHAI developed these frequently asked questions (FAQs) to lay out information for communities and PLHIV on the subject of DRV/r (400/50...
222
Mar 22, 2022
Customizable Adult DRV/r (400/50mg) Healthcare Worker Training Slides
CHAI has developed a generic training curriculum that is intended to be adapted for local contexts and their respective training plans.
134
Mar 17, 2022
Adult DRV/r (400/50mg) Clinical Action Memo
Darunavir (DRV) is a best-in-class protease inhibitor (PI) used in combination with other antiretroviral (ARV) drugs for the...
298
Mar 17, 2022
Customizable Adult DRV/r (400/50mg) Prescribing Algorithm
CHAI is pleased to share a customizable guide to assist healthcare workers with prescribing and dispensing second-line (2L) DRV/r...
118
Mar 16, 2022
CHAI DRV/r 2L Product Profile
A presentation with the latest information on DRV/r (400/50mg) and considerations for adult second line treatment optimization.
173
Mar 16, 2022
DRV/r (400/50mg) FAQs
CHAI developed these frequently asked questions (FAQs) to lay out information for national HIV programs considering the adoption and...
85
Jan 1, 2021
CHAI National Stock Status Dashboard
Keeping an adequate stock of ARVs on hand is important for multiple reasons. Too much stock, and programs run the risk of products...
66
Jan 1, 2021
CHAI Rapid Consumption Monitoring Tool
As national programs continue to rollout new generic ARVs, there is a need for routine, careful monitoring of product uptake to ensure...
48
bottom of page